RecruitingFollicular LymphomaMarginal Zone Lymphoma
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evaluated separately. This study is presented to the patient and consent is signed prior to the initiation of treatment for their primary malignancy.
Sponsor: Masonic Cancer Center, University of Minnesota
You may qualify if…
- ✓ Histologically confirmed marginal zone lymphoma
- ✓ Histologically confirmed CD20+ follicular lymphoma stage 1, 2 or 3a
- ✓ No prior systemic therapy for lymphoma
- ✓ Must be in need of treatment as evidenced by one or more of the following criteria:
- ✓ Bulky disease defined as:
- ✓ a nodal or extranodal (except spleen) mass \>7cm in its greater diameter or,
- ✓ involvement of at least 3 nodal or extranodal sites (each with a diameter greater than \>3 cm)
- ✓ Presence of at least one of the following B symptoms:
You may not qualify if…
- ✕ Seropositive for or active viral infection with hepatitis B virus (HBV):
- ✕ HBV surface antigen (HBsAg) positive
- ✕ HBV surface antigen (HBsAg) negative, HBV surface antibody (anti-HBs) positive and/or HBV core antibody (anti-HBc) positive, and detectable viral DNA
- ✕ Hepatitis C virus (HCV) positive subjects with chronic hepatitis C, or subjects with an active hepatitis C infection requiring anti-viral medication (at time of randomization).
- ✕ Known seropositive for or active viral infection with human immunodeficiency virus (HIV).
- ✕ Prior history of lenalidomide use
- ✕ Prior history of malignancies, other than follicular or marginal zone lymphoma, unless the subject has been free of the disease for ≥ 5 years.
- ✕ Peripheral neuropathy ≥ grade 2 at time of screening
Where it's recruiting
Minnesota
Minneapolis
Source: ClinicalTrials.gov · NCT06792825 · last updated 2026-08-12